129 related articles for article (PubMed ID: 22112480)
1. The molecular pathology of cutaneous melanoma.
Bogenrieder T; Herlyn M
Cancer Biomark; 2010; 9(1-6):267-86. PubMed ID: 22112480
[TBL] [Abstract][Full Text] [Related]
2. Treatment implications of the emerging molecular classification system for melanoma.
Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
4. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
5. Melanoma mutagenesis and aberrant cell signaling.
Bello DM; Ariyan CE; Carvajal RD
Cancer Control; 2013 Oct; 20(4):261-81. PubMed ID: 24077403
[TBL] [Abstract][Full Text] [Related]
6. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
Haluska F; Pemberton T; Ibrahim N; Kalinsky K
Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeted therapy for melanoma.
Friedlander P; Hodi FS
Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
Takata M; Murata H; Saida T
Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
[TBL] [Abstract][Full Text] [Related]
9. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
10. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.
Liu ZJ; Xiao M; Balint K; Smalley KS; Brafford P; Qiu R; Pinnix CC; Li X; Herlyn M
Cancer Res; 2006 Apr; 66(8):4182-90. PubMed ID: 16618740
[TBL] [Abstract][Full Text] [Related]
11. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
12. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
13. Functional and therapeutic significance of Akt deregulation in malignant melanoma.
Robertson GP
Cancer Metastasis Rev; 2005 Jun; 24(2):273-85. PubMed ID: 15986137
[TBL] [Abstract][Full Text] [Related]
14. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
15. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of cutaneous melanocytic neoplasms.
Ibrahim N; Haluska FG
Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors in the treatment of metastatic melanoma.
Kalinsky K; Haluska FG
Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.
Pópulo H; Soares P; Rocha AS; Silva P; Lopes JM
Melanoma Res; 2010 Apr; 20(2):107-17. PubMed ID: 20173664
[TBL] [Abstract][Full Text] [Related]
20. [Kinase inhibitors for the therapy of malignant melanoma].
Becker JC; Schrama D; Bröcker EB; Houben R
J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
